Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Malachy I, Okeke"'
Autor:
Roland I. Stephen, Jamiu S. Olumoh, Jimmy A. Reyes, Malachy I. Okeke, Jennifer A. Tyndall, Nura Umaru, Oyelola A. Adegboye
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/656c154ceaa543ef837957bdb9731e83
Autor:
Daniel B. Kolawole, Malachy I. Okeke
Publikováno v:
Osong Public Health and Research Perspectives, Vol 13, Iss 2, Pp 101-113 (2022)
Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). The COVID-19 incidence and mortality rates are low in Nigeria compared to global trends. This research mapped the e
Externí odkaz:
https://doaj.org/article/0a3df777a54149699f11c5415a0b0f1c
Autor:
Oyelola A. Adegboye, Faith O. Alele, Anton Pak, Maria E. Castellanos, Mohammed A.S. Abdullahi, Malachy I. Okeke, Theophilus I. Emeto, Emma S. McBryde
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/9a5d746f247248939dc9566d7b014fcd
Autor:
Emmanuel F, Alakunle, Malachy I, Okeke
Publikováno v:
Nature reviews. Microbiology. 20(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::312fb70f40c374141c1eb19592b4cd9b
https://pubmed.ncbi.nlm.nih.gov/35882992
https://pubmed.ncbi.nlm.nih.gov/35882992
Publikováno v:
Viruses, Vol 10, Iss 1, p 50 (2018)
The clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein 9 (Cas9) technology is revolutionizing genome editing approaches. Its high efficiency, specificity, versatility, flexibility, simplicity and low cost have made t
Externí odkaz:
https://doaj.org/article/d731f4dc021e411aa5377bafb9fa999d
Autor:
Malachy I. Okeke, Arinze S. Okoli, Diana Diaz, Collins Offor, Taiwo G. Oludotun, Morten Tryland, Thomas Bøhn, Ugo Moens
Publikováno v:
Viruses, Vol 9, Iss 11, p 318 (2017)
Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary applications due to its strong safety profile and immunogenicity in vivo. The use of MVA and MVA-vectored vaccines against human and animal diseases must comply wit
Externí odkaz:
https://doaj.org/article/5905ff8234be4649a0e5dbe6841e4a21